Call Now Open

Oxford-Harrington Rare Disease Scholar Award

You've just added:

Home / News

News + Media

February 06, 2024

Oxford-Harrington Rare Disease Centre Opens Call for Proposals

New Scholar Award Accelerates Novel Therapies for Rare Diseases Continue Reading

January 03, 2024

Jonathan Stamler, MD, Named Fellow of the 2023 National Academy of Inventors

Co-founder and president of Harrington Discovery Institute at University Hospitals receives highest professional distinction awarded solely to inventors Continue Reading

December 21, 2023

Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults

The study showed that all doses of ALX-001 were well tolerated, up to and including levels high enough to achieve full brain target engagement, supporting the company’s plans to continue clinical development for the treatment of Alzheimer’s disease. Continue Reading

December 13, 2023

Harrington Family Honored: The Faces of Life-Saving New Medicines

The Harrington Family has been recognized in Cleveland Magazine's 2023 Faces of Cleveland as "The Faces of Life-Saving New Medicines" Continue Reading

December 08, 2023

Wisconsin scientists studying gene-editing tech to cure blindness

Similar technology is gaining regulatory approval to treat sickle cell disease and drawing research attention to treat a wide range of health concerns Continue Reading

December 05, 2023

An Enzyme that Selectively S-nitrosylates Proteins to Regulate Insulin Signaling

New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease Continue Reading

November 30, 2023

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Sol-Gel Technologies, a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, begun Phase 3 testing of SGT-610 for Gorlin syndrome with the first patient screened. Continue Reading

October 25, 2023

Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Dis

ABX1100 is a first-in-class molecule representing a new approach to reducing toxic levels of glycogen that build up in muscles of patients with Pompe Disease. Continue Reading

October 18, 2023

2021-2022 Harrington Annual Publication

First Ten Years. Accelerating Discoveries into Medicines. Continue Reading

October 04, 2023

Aerium Therapeutics Advances Next Generation Antibodies to Protect Immunocompromised Persons Against COVID-19

Monoclonal antibodies could provide a much-needed tool to protect vulnerable populations from severe COVID-19 Continue Reading